spacer
home > ebr > spring 2007 > the legal implications of phase i clinical trials
PUBLICATIONS
European Biopharmaceutical Review

The Legal Implications of Phase I Clinical Trials

Anthony Warnock-Smith, Partner and Head of the life sciences group at the London office of Morgan Lewis examines the future role of Phase I clinical trials in the light of the recent disastrous TeGenero experience

Phase I clinical studies in healthy volunteers are, from a legal perspective, inherently problematic – a fact that was illustrated recently by the lifethreatening side-effects experienced by the six healthy volunteers who took part in the now infamous TeGenero Phase I trial of its monoclonal antibody product, TGN1412.

Phase I studies are never without risk, largely because the medicine being tested has, at that stage, only been tested theoretically and in animals. Despite this, there has only been a small level of personal injury among Phase I volunteers since current legal and clinical practice procedures were introduced in the 1970s, including just one recorded death.

The severe reactions of the volunteers in the TeGenero trial are thought to have occurred because the type of drug being tested – a monoclonal antibody which is a form of biological medicine – was designed explicitly to target a specific human protein. The prior animal tests that were conducted using the drug revealed no drug-related adverse events, probably because the artificial antibodies in the drug were designed to latch onto human protein only.

The failure of TGN1412 is a significant blow for what has been regarded as one of the most promising sub-categories of the relatively new monoclonal antibody class of drugs, and could have negative implications for development within this drug category, which is thought to show potential in the treatment of diseases such as cancer, immune and inflammatory disorders. Beyond the potential set-back of this sub-category, the TeGenero incident is likely to have even greater consequences for clinical trials in general, because it has caused the pharmaceutical industry and the regulatory authorities in the EU to revisit the safeguards put in place for Phase I studies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
3
     

There are no comments in regards to this article.

spacer
Anthony Warnock-Smith, Partner and Head of the life sciences group at the London office of Morgan Lewis examines the future role of Phase I clinical trials in the light of the recent disastrous TeGenero experience
spacer
Anthony Warnock-Smith
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement